

CURRICULUM VITAE**ILANA F. GAREEN****PERSONAL INFORMATION**

Address: Department of Epidemiology
Center for Statistical Sciences
Brown University School of Public Health
121 South Main, S-121-7
Providence, RI 02912

Phone: (401) 863-1758
E-mail: igareen@stat.brown.edu

EDUCATION

1982	A.B.	Bioethics	Vassar College
1985	M.P.H.	Epidemiology	Yale University School of Medicine
1997	Ph.D.	Epidemiology	University of California, Los Angeles
1997-1999	Post-doctoral Fellow	Center for Statistical Sciences	Brown University

ACADEMIC APPOINTMENTS

2015-present	Associate Professor	Epidemiology	Brown University
1999-2015	Assistant Professor	Epidemiology	Brown University
1997-1999	Research Fellow	Community Health	Brown University
1997-1999	Research Fellow	Diagnostic Imaging	Brown University
1993	Teaching Assistant	Epidemiology	University of California, Los Angeles
1987-1989	Research Associate	Public Health	Cornell University Medical College

OTHER APPOINTMENTS:

2014-present	Affiliate Member	Center for Evidence-Based Medicine
1997-present	Member	Center for Statistical Sciences, Brown University

HONORS AND AWARDS:

2008	American College of Radiology Imaging Network Outstanding Contribution Award
2002	American College of Radiology Imaging Network Outstanding Contribution Award
1989-1992	Pew Health Policy Fellow, RAND/University of California, Los Angeles

SERVICE AND ACTIVITIES**Departmental**

2024-2025	Member, Epidemiology Ph.D. Admissions Committee
2024	Epidemiology Standards and Promotion Criteria Committee
2020-2022	Member, Epidemiology Curriculum Committee
2018-2019	Department of Epidemiology Faculty Search Committee
2016-2019	Member, Epidemiology Ph.D. Admissions Committee
2015-2016	Member, Epidemiology Curriculum Committee

2004-2013 Member, Epidemiology Curriculum Committee

University

2022 HSPP and Center for Evidence Based Medicine Faculty Search Committee
 2017-present Member, Center for Statistical Sciences Executive Committee
 2015-2019 Member, Ad Hoc Committee on Research Faculty
 2014-2017 Member Recruitment Committee: K12: Develop Patient Centered Outcomes Scholars for Comparative Effectiveness Research
 2003-2004 Member, Faculty Search Committee, Center for Clinical Trials

Leadership Committees

2023-present Member ECOG-ACRIN Patient Report Outcomes Advisory Group
 2018-present Co-Chair ECOG-ACRIN Cancer Research Group, Patient-Reported Outcomes Working Group
 2017-present Co-Chair ECOG-ACRIN Cancer Research Group, Late Effects Working Group
 2014-present Co-Chair ECOG-ACRIN National Community Oncology Research Program, Cancer Care Delivery Research Committee
 2014-2019 Chair ECOG-ACRIN Cost-Effectiveness Cross-Cutting Committee
 2002-present Director ECOG-ACRIN Outcome and Economics Assessment Unit
 2002-2014 Director ACRIN Outcome and Economics Core Laboratory
 2002-2011 Member National Lung Screening Trial Executive Committee
 1999-2014 Member ACRIN Outcomes Committee

Expert Panels

2023-present Member National Cancer Institute ePRO Working Group
 2021 Moderator Asia-Pacific Economic Cooperation forum (APEC) virtual workshop on Cancer Control Policy – Thematic Session 2: Screening and Early Detection, Accelerating Implementation of Cancer Control Programs in APEC Economies through Innovation and Partnership, facilitated by the APEC Life Sciences Innovation Forum on behalf of the Ministry of Health and Welfare (MoHW), Chinese Taipei
 2020-2023 Member Advisory Panel on Clinical Trials, Patient-Centered Outcome Research Institute
 2013 Member Centers for Disease Control Expert Panel on Lung Cancer Screening Surveillance
 2012 Member Planning Committee, Symposium on Comparative Effectiveness of Advanced Imaging in Cancer
 2010-2013 Member Data Safety Monitoring Board, “Protective Effects of Delayed Cord Clamping in Very Low Birth Weight Infants”
 2008-2012 Co-Chair National Lung Screening Trial, Epidemiology Working Group
 2008 Member National Institutes of Health, Office of the Director, Office of Medical Applications of Research (OMAR), and the National Institute of Diabetes and Digestive and Kidney Diseases, NIH Consensus Development Conference: Management of Hepatitis B. 2008
 2007 Member Promotion Committee, Corinne Aragaki

2003-2006	Co-Chair	The National Cancer Institute's NLST Smoking Working Group on Risk Perception
2000-2001	Member	National Cancer Institute, Panel on Common Data Elements for Helical CT Screening of Lung Cancer

Grant Application Review Boards

2024	Scientific Reviewer	Veteran's Affairs clinical trials/translational studies
2023	Scientific Reviewer	Diagnosis, Detection and Prognosis panel of the FY23 LCRP for the Department of Defense Congressionally Directed Medical Research Program (CDMRP)
2021-2022	Member	Health Services: Quality and Effectiveness Study Section, Center for Scientific Review, National Institutes of Health
2018-2020	Member	Health Services Organization and Delivery Study Section, Center for Scientific Review, National Institutes of Health
2017	Member	NIH Special Emphasis Panel 2017/10 ZCA1 SRB-5 (O1) R: NCI Research and Coordinating Center for Population-based Research to Optimize the Screening Process Review Meeting
2017	Member	NIH Special Emphasis Panel ZRG1 PSE-H 50: Cancer-Related Behavioral Research through Integrating Existing Data applications. Center for Scientific Review, National Institutes of Health
2017	Temporary Member	Health Services Organization and Delivery Study Section, Center for Scientific Review, National Institutes of Health
2016-2017	Scientific Reviewer	Applied clinical and biomedical research was launched by the Italian Ministry of Health (MOH)
2016	Temporary Member	Health Services Organization and Delivery Study Section, Center for Scientific Review, National Institutes of Health

Editorial Responsibilities

2017-present	Member, Cancer Control, 2017
2014-2017	Academic Editor, Medicine, 2014
2004-2012	Associate Editor, Epidemiologic Perspectives & Innovations, 2004

Journal Manuscript Reviewer

American Journal of Radiology, American Thoracic Society, BMC Primary Care, Cancer, Chest, Generating Evidence & Methods to improve patient outcomes, JAMA, Journal of Clinical Oncology, Journal of Nuclear Medicine, Journal of Patient-Reported Outcomes, Journal of Psychosomatic Research
Journal of the American College of Radiology, Journal of Clinical Oncology, Medical Care, Obstetrics & Gynecology, Radiology, Respiriology, Statistics in Medicine

PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Staiano-Coico L, Wong R, Jacobsen I, Morrissey KP, Lesser ML, **Gareen IF**, McMahon C, Cennerazzo W, Decosse J. DNA Content of Rectal Scrapings From Individuals with Familial Adenomatous Polyposis Syndrome: An Interim Report. *Cancer* 1989;64:2579-2584.
2. Wojtasek DA, Texidor HS, Govini AF, and **Gareen IF**. Diagnostic Quality of Mammograms Obtained with A New Low-Radiation-Dose Dual-Screen and Dual-Emulsion Film Combination. *AJR* 1990;154:265-270.
3. Dicostanzo D, Rosen PP, **Gareen I**, and Lesser M. Prognosis in Infiltrating Lobular Carcinoma: An Analysis Of "Classical" And Variant Tumors. *Am J Surg Pathol* 1990;14:12-23.
4. **Gareen I**, Greenland S, and Morgenstern H. Intrauterine Devices and Pelvic Inflammatory Disease: Meta-analyses of Published Studies, 1974-1990 *Epidemiology* 2000;11:589-597.
5. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa De Echaguen A, **Gareen IF**, Reiss PT, Medeiros AA. Failure Of Macrolide Antibiotic Treatment in Patients with Bacteremia Due To Erythromycin-Resistant *Streptococcus Pneumoniae*. *Clin Infect Dis*. 2002;35:556-64.
6. Mainiero MB, **Gareen IF**, Bird CE, Smith W, Cobb C, Schepps B. Preferential use of sonographically guided biopsy to minimize patient discomfort and procedure time in a percutaneous image-guided breast biopsy program. *J Ultrasound Med* 2002;21:1221-1226.
7. Mayo-Smith WW, Rhea JT, Smith WJ, Cobb CM, **Gareen IF**, Dorfman GS. Transportable versus fixed platform CT scanners: comparison of costs. *Radiology*. 2003;226:63-8.
8. **Gareen IF**. Intrauterine devices and pelvic inflammatory disease. *Curr Womens Health Rep*. 2003;3:280-7.
9. **Gareen I**, Gatsonis C. A primer on multiple regression models for diagnostic imaging research, *Academic Radiology*, 2003;229:305-10.
10. **Gareen I**, Morgenstern H, and Greenland S. Explaining the association of maternal age with cesarean delivery for nulliparous and parous women, *J Clin Epidemiol*. 2003; 56: 1100-10.
11. Church T. and NLST Executive Committee Chest radiography as the comparison for spiral CT in the National Lung Screening Trial. *Academic Radiology*, 2003;10:713-715. PMID:12809426.
12. Lazarus E, Mainiero MB, **Gareen IF**. Effect of referring physician specialty and practice type on referral for image-guided breast biopsy. *Journal of the American College of Radiology*, 2005;2:488-493.
13. **Gareen IF**, Non-compliance in cancer screening trials, *Clinical Trials*. 2007;4(4):341-9.
14. Hillner BE, Liu D, Coleman RE, Shields AF, **Gareen IF**, Hanna L, Stine SH, Siegel BA. The National Oncologic PET Registry (NOPR): design and analysis plan. *J Nucl Med*. 2007 Nov;48(11):1901-8.
15. Hillner BE, Siegel BA, Liu D, Shields AF, **Gareen IF**, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. *J Clin Oncol*. 2008 May 1;26(13):2155-61.
16. Belongia EA, Costa J, **Gareen IF**, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Sorrell MF, Strader DB, Trotter HT. NIH Consensus Development Statement on Management of Hepatitis B. *NIH Consens State Sci Statements*. 2008 Oct 22-24;25(2):1-29.
17. Hillner BE, Siegel BA, Shields AF, Liu D, **Gareen IF**, Hunt E, Coleman RE. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. *J Nucl Med*. 2008 Dec;49(12):1928-35.
18. Hillner BE, Siegel BA, Shields AF, Liu D, **Gareen IF**, Hanna L, Stine SH, Coleman RE. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the

- National Oncologic PET Registry. *Cancer*. 2009 Jan 15;115(2):410-8.
19. Sorrell MF, Belongia EA, Costa J, **Gareen IF**, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. *Ann Intern Med*. 2009 Jan 20;150(2):104-10.
 20. Sorrell MF, Belongia EA, Costa J, **Gareen IF**, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. *Hepatology*. 2009 May;49(5 Suppl):S4-S12.
 21. Park ER, Ostroff JS, Rakowski W, **Gareen IF**, Diefenbach MA, Feibelmann S, Rigotti NA. Risk perceptions among participants undergoing lung cancer screening: baseline results from the national lung screening trial. *Ann Behav Med*. 2009 Jun;37(3):268-79.
 22. National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, **Gareen IF**, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: Overview and Study Design. *Radiology*. 2010 Nov 2. *Radiology*. 2011 Jan;258(1):243-53.
 23. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, **Gareen IF**, Lynch DA, Marcus PM, Pinsky PF. Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. *J Natl Cancer Inst*. 2010 Dec 1;102(23):1771-9.
 24. Hillner BE, Siegel BA, Shields AF, Duan F, **Gareen IF**, Hanna L, Coleman RE. Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry. *Mol Imaging Biol*. 2011 Feb;13(1):161-5.
 25. Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, **Gareen IF**, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. *Radiology*. 2011 Nov;261(2):487-98.
 26. Arthur E. Stillman, MD, PhD; Pamela K. Woodard, MD; RESCUE Investigators. Consequence of Overuse of Invasive Coronary Angiography. *Arch Intern Med*. 2011;171(7):702-710.
 27. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, **Gareen IF**, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011 Aug 4;365(5):395-409.
 28. Marcus PM, **Gareen IF**, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death. *Contemp Clin Trials*. 2011 Nov;32(6):834-40.
 29. Hillner BE, Siegel BA, Hanna L, Shields AF, Duan F, **Gareen IF**, Quinn B, Coleman RE. Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts. *J Nucl Med*. 2012 May;53(5):831-7.
 30. **Gareen IF**, Sicks J, Adams A, Moline D, Coffman-Kadish N, Aberle DR. Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: The model used by the American College of Radiology arm of the National Lung Screening Trial. *Contemp Clin Trials*. 2013 Jan;34(1):36-44.
 31. Park ER, **Gareen IF**, Jain A, Ostroff JS, Duan F, Sicks JD, Rakowski W, Diefenbach M, Rigotti NA. Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up. *Cancer*. 2013 Apr 1;119(7):1306-13.
 32. National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, **Gareen IF**, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S.

Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med.* 2013 May 23;368(21):1980-91.

33. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, **Gareen IF**, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. *N Engl J Med.* 2013 Sep 5;369(10):920-31.
34. Park ER, Streck JM, **Gareen IF**, Ostroff JS, Hyland KA, Rigotti NA, Pajolek H, Nichter M. A Qualitative Study of Lung Cancer Risk Perceptions and Smoking Beliefs Among National Lung Screening Trial Participants. *Nicotine Tob Res.* 2013 Sep 2.
35. **Gareen IF**, Duan F, Greco EM, Snyder BS, Boiselle PM, Park ER, Fryback D, Gatsonis C. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. *Cancer.* 2014 Nov 1;120(21):3401-9.
36. Black WC, **Gareen IF**, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, Gatsonis C; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med.* 2014 Nov 6;371(19):1793-802.
37. Clark MA, Gorelick JJ, Sicks JD, Park ER, Graham AL, Abrams DB, **Gareen IF**. The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Cancer Screening Trial: Implications for Public Health. *Nicotine Tob Res.* 2015 Mar 6.
38. Park ER, **Gareen IF**, Japuntich S, Lennes I, Hyland K, DeMello S, Sicks JD, Rigotti NA. Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. *JAMA Intern Med.* 2015 Jun 15.
39. **Gareen IF**, Siewert B, Vanness DJ, Herman B, Johnson CD, Gatsonis C. Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial. *Patient Prefer Adherence.* 2015 Jul 23;9:1043-51.
40. Kumar P, **Gareen IF**, Lathan C, Sicks JD, Perez G, Hyland K, Park ER. Racial differences in tobacco cessation and treatment utilization following lung screening: an examination of the National Lung Screening Trial. *Oncologist.* 2016 Jan;21(1):40-9.
41. Marcus PM, Doria-Rose VP, **Gareen IF**, Brewer B, Clingan K, Keating K, Rosenbaum J, Rozjabeck HM, Rathmell J, Miller AB. Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial? *Clin Trials.* 2016 Mar 22.
42. Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB 3rd, Rapkin BD, Weiss ES, **Gareen IF**, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB. Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. *J Oncol Pract.* 2016 Nov;12(11):1101-1113.
43. Stillman AE, Gatsonis C, Lima JA, Black WC, Cormack J, **Gareen I**, Hoffmann U, Liu T, Mavromatis K, Schnall MD, Udelson JE, Woodard PK. Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial. *Am Heart J.* 2016 Sep;179:19-28.
44. **Gareen IF**, Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Siegel B. Hospice Admission and Survival following (18)F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. *J Nucl Med.* 2017 Dec 28.
45. Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, **Gareen I**, Siegel BA. Intended vs. Inferred Treatment after (18)F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. *J Nucl Med.* 2017 Nov 30.

46. **Gareen IF**, Black WC, Tosteson T, Wang Q, Tosteson A. Medical costs were similar across the CT and chest X-ray arms of the National Lung Screening Trial despite different rates of significant incidental findings. 2018 May;56(5):403-409.
47. Perez GK, **Gareen IF**, Sicks J, Lathan C, Carr A, Kumar P, Ponzani C, Hyland K, Park ER. Racial Differences in Smoking-related Disease Risk Perceptions Among Adults Completing Lung Cancer Screening: Follow-up Results from the ACRIN/NLST Ancillary Study. *J Racial Ethn Health Disparities*. 2019 Feb 8.
48. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, **Gareen I**, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. *JAMA*. 2019 Apr 2;321(13):1286-1294.
49. Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, **Gareen I**, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C. Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. *JAMA Oncol*. 2019 Jan 17.
50. Corl KA, Prodromou M, Merchant RC, **Gareen I**, Marks S, Banerjee D, Amass T, Abbasi A, Delcompare C, Palmisciano A, Aliotta J, Jay G, Levy MM. The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study. *Crit Care Med*. 2019 Jul;47(7):951-959.
51. National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. *J Thorac Oncol*. 2019 Oct;14(10):1732-1742.
52. Comstock CE, Gatsonis C, Newstead GM, Snyder BS, **Gareen IF**, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. *JAMA*. 2020 Feb 25;323(8):746-756.
53. Chou SS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberry JR, **Gareen IF**, Snyder BS, Gatsonis C, Wagner LI, Wolff AC, Miller KD, Sparano JA, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). *Radiology*. 2021 Aug 3:204743.
54. Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SF, **Gareen IF**, Whelan TJ, Sledge GW, Cella D, Wagner LI. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncol*. 2021 Jun 17.
55. Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, **Gareen IF**, Whelan TJ, Sledge GW, Cella D, Wagner LI. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. *Cancer*. 2022 Feb 1;128(3):536-546.
56. Fazeli S, Snyder BS, **Gareen IF**, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Miller KD, Sparano JA, Comstock CE, Wagner LI, Carlos RC. Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Netw Open*. 2021 Nov 1;4(11):e2129697.
57. Ip EH, Saldana S, Miller KD, Carlos RC, **Gareen IF**, Sparano JA, Graham N, Zhao F, Lee JW, O'Connell NS, Cella D, Peipert JD, Gray RJ, Wagner LI. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. *Cancer*. 2021 Dec 15;127(24):4546-4556.
58. Bradbury AR, Lee JW, Gaieski JB, Li S, **Gareen IF**, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ,

- Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). *Cancer*. 2022 Apr 1;128(7):1381-1391.
59. Carlos RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, Pisano ED, Troester MA, Timsina L, Wagner LI, Steingrimsson JA, **Gareen I**, Lee CI, Adams AS, Wilkins CH. Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. *J Clin Oncol*. 2022 Feb 2;JCO2102004.
 60. Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Obeng-Gyasi S, **Gareen I**, Sledge GW, Whelan TJ, Cella D, Wagner LI, Carlos RC. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncol*. 2022 Apr 1;8(4):579-586.
 61. Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, **Gareen IF**, Timsina LR, Gray R, Wagner LI, Carlos RC. Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. *Blood Cancer J*. 2022 Apr 1;12(4):53.
 62. Fazeli S, Snyder BS, **Gareen IF**, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, Sparano JA, Comstock CE, Wagner LI, Carlos RC. Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Network Open*. 2022 May 2;5(5):e2210331.
 63. Goshe BM, Rasmussen AW, Wagner LI, Sicks JD, **Gareen IF**, Carlos RC, Herman BA, Walter AW, Regan S, Levy DE, Mahon I, Muzikansky A, Neil JM, Lui M, Dilip D, Malloy L, Gonzalez I, Finkelstein-Fox L, McCann C, Perez E, Ostroff JS, Park ER. Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]. *BMC Public Health*. 2022 Jul 15;22(1):1359.
 64. Ghazal LV, Cole S, Salsman JM, Wagner L, Duan F, **Gareen I**, Lux L, Parsons SK, Cheung C, Loeb DM, Prasad P, Dinner S, Zebrack B. Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. *JCO Precis Oncol*. 2022 Jun;6:e2100462.
 65. Wilkins CH, Windon CC, Dilworth-Anderson P, Romanoff J, Gatsonis C, Hanna L, Apgar C, **Gareen IF**, Hill CV, Hillner BE, March A, Siegel BA, Whitmer RA, Carrillo MC, Rabinovici GD. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals with Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. *JAMA Neurol*. 2022 Oct 3;79(11):1139-47.
 66. **Gareen IF**, Gutman R, Sicks J, Tailor TD, Hoffman RM, Trivedi AN, Flores E, Underwood E, Cochancela J, Chiles C. Significant Incidental Findings in the National Lung Screening Trial. *JAMA Intern Med*. 2023 Jul 1;183(7):677-684.
 67. **Gareen IF**, Hoffman RM, Tailor TD. Separating Actionable from Incidental Findings-Imperative for Meaningful Clinical Outcomes-Reply. *JAMA Intern Med*. 2023 Oct 1;183(10):1176-1177.
 68. Rabinovici GD, Carrillo MC, Apgar C, **Gareen IF**, Gutman R, Hanna L, Hillner BE, March A, Romanoff J, Siegel BA, Smith K, Song Y, Weber C, Whitmer RA, Gatsonis C. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia. *JAMA Neurol*. 2023 Nov 1;80(11):1166-1173.
 69. Narayan V, Liu T, Song Y, Mitchell J, Sicks J, **Gareen I**, Sun L, Denduluri S, Fisher C, Manikowski J, Wojtowicz M, Vadakara J, Haas N, Margulies KB, Ky B. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients with Renal Cell Carcinoma and Thyroid Cancer Treated with VEGFR TKIs. *J Natl Compr Canc Netw*. 2023 Oct;21(10):1039-1049.e10.

70. Lin MY, Liu T, Gatsonis C, Sicks JD, Shih S, Carlos RC, **Gareen IF**. Utilization of Diagnostic Procedures After Lung Cancer Screening in the National Lung Screening Trial. *J Am Coll Radiol*. 2023 Oct;20(10):1022-1030.
71. O'Connell NS, Zhao F, Lee JW, Ip EH, Peipert JD, Graham N, Smith ML, **Gareen IF**, Carlos RC, Obeng-Gyasi S, Sparano JA, Shanafelt TD, Thomas ML, Cella D, Wagner LI, Gray R. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. *J Clin Oncol*. 2024 Jan 20;42(3):266-272.
72. Walter AW, Lee JW, Streck JM, **Gareen IF**, Herman BA, Kircher SM, Carlos RC, Kumar SK, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land SR, Ostroff JS, Park ER. The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials. *Cancer*. 2024 Feb 1;130(3):439-452.
73. Streck JM, Lee JW, Walter AW, Rosen RL, **Gareen IF**, Kircher SM, Herman BA, Carlos RC, Kumar S, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials. *Cancer Epidemiol Biomarkers Prev*. 2023 Nov 1;32(11):1552-1557.
74. Kircher S, Duan F, An N, **Gareen IF**, Sicks JD, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC. Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer. *JAMA Netw Open*. 2024 Jan 2;7(1):e2350844.
75. Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O'Connell N, Carlos RC, Graham N, Smith ML, **Gareen IF**, Raper PJ, Weiss M, Kumar SK, Rajkumar SV, Cella D, Gray R, Wagner LI. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. *JAMA Netw Open*. 2024 Mar 4;7(3):e243854.
76. Sadigh G, Duan F, An N, **Gareen IF**, Sicks JD, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Taylor MA, Park ER, Wagner LI, Kircher S, Carlos RC. Longitudinal Changes of Financial Hardship in Early Stage Colorectal Cancer: Results of EAQ162CD In press, *JAMA Network Open* (in press).
77. **Gareen IF**, Gutman R, Song Y, Trivedi A, Flores E, Tailor T, Chiles C, Sicks J, Hoffman R. Significant Incidental Findings Were Not Associated with Medical Complications in the NLST. (submitted)
78. Tailor T, Gutman R, An N, Hoffman R, Carlos R, Sicks J, **Gareen IF**. Lung Cancer Screening in Practice: A comparison of Results in a National Screening Population versus the National Lung Screening Trial (submitted)
79. Price SN, Lee J-W, **Gareen IF**, Kircher S, Kumar SK, Mayer I, Saba NF, Fenske TS, Atkins MB, Hodi SF, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Park ER, Wagner LI. Cigarette smoking, symptom burden, and symptom management perspectives among adults with cancer: baseline results from 9 ECOG-ACRIN clinical trials, (draft).
80. Diamond B, Duan F, Bo Y, Thangarajah M, Sicks J, **Gareen IF**. Collection of Oncology Patient Reported Outcomes using Electronic versus Mail Format: the ECOG-ACRIN experience (draft)
81. **Gareen IF**, Gutman R, Thangarajah M, Trivedi A, Tailor T, Flores E, Chiles C, Hoffman R. Significant Incidental Findings were associated with the diagnosis of Extrapulmonary Cancer Diagnosis in the National Lung Screening Trial (draft)
82. Tailor T, Gutman R, Song Y, Hoffman R, Carlos R, Sicks J, **Gareen IF**. Health Care Utilization, lung cancer diagnosis, and lung cancer mortality following lung cancer screening in the community versus the National Lung Screening Trial (draft)

83. **Gareen IF**, Gutman R, Song Y, Trivedi A, Taylor T, Boame N, Flores E, Chiles C, Hoffman R. Detection of Significant Incidental Findings in the Community versus the National Lung Screening Trial (draft)
84. **Gareen IF**, Gutman R, Song Y, Trivedi A, Taylor T, Flores E, Chiles C, Hoffman R. Association between detection of significant incidental findings and mortality in the National Lung Screening Trial (draft)

NON-PEER REVIEWED PUBLICATIONS

Morgenstern H, **Gareen IF**, Senterfitt JW, Greenland S. Intrauterine-device Use and Pelvic Inflammatory Disease: A Meta-analysis of Published Results, 1974-90. Report to the Dalkon Shield Claimants Trust, 1994.

Gatsonis, C, Carlos R, **Gareen I**, Gorelick J, Kessler L, Lau J, Rutter C, Schmid C, Tosteson A, Trikalinos T. Standards in the Design, Conduct and Evaluation of Diagnostic Testing For Use in Patient Centered Outcomes Research. 2012. Available at <http://www.pcori.org/assets/Standards-in-the-Design-Conduct-and-Evaluation-of-Diagnostic-Testing-for-Use-in-Patient-Centered-Outcomes-Research.pdf>

INVITED PRESENTATIONS

Invited Speaker, National Lung Cancer Roundtable, Actual versus Recommended Follow-up in the National Lung Screening Trial, October 2023.

Invited Speaker, Cancer Population Sciences Program, Legorreta Cancer Center, The Issue of Significant Incidental Findings Detected at Lung screening, June 2023.

Invited Speaker, ECOG-ACRIN Spring Meeting, E-A Outcomes and Economics Assessment Unit PRO Data Collection, April 2023.

Invited Speaker, ECOG-ACRIN Fall Meeting, ECOG-ACRIN Systems for Easy Entry of Patient Reported Outcomes (EASEE-PRO), November 2021.

Invited Speaker, ECOG-ACRIN Fall Meeting, Equity Indicators and PRO Response Rates, October 2020.

Invited Speaker, ECOG-ACRIN Fall Meeting, EAQ191 CARISMA Cancer Therapy Risk-Reduction with Intensive Systolic Blood Pressure (SBP) Management – a Phase II Trial (R34 HL146927), October 2020.

Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2019.

Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2018.

Invited Speaker, Dana Farber/Harvard Cancer Center Cancer Care Delivery Research Seminar, “Lung screening: research into comparative costs in the low-dose CT and chest X-ray arms of the National Lung Screening Trial, the importance of significant incidental findings, and planned work to compare lung screening efficacy in the NLST versus effectiveness in community lung screening.” February 6, 2018.

Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2017.

Panel member PCORI at ECOG-ACRIN Annual Meeting, Washington, DC, May 2017.

Panel member ECOG-ACRIN/Patient Centered Outcomes Research Institute Comparative Effectiveness Research Workshop, Feb 2017

Invited Speaker, Lung Cancer Screening, Cancer Grand Rounds, Rhode Island Hospital, June 11, 2015.

Invited Speaker, Lung Cancer Screening: A Debate of Practice, Policy, and Science, Society for Medical Decision Making, October 18, 2014.

Invited Panel Member, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging II, October 18-19, 2012.

- Panel Member, Lung Cancer Screening: Accomplishments and Challenges, Symposium on Comparative Effectiveness of Advanced Imaging in Cancer, April 30, 2012.
- Invited Speaker, National Cancer Institute Risk Perception Branch, "Smoking Behavior Data Collected in the ACRIN arm of the National Lung Screening Trial (NLST)," October 11, 2011.
- Invited Speaker, ACRIN Plenary Session, "Smoking Cessation Behavior in the National Lung Screening Trial (NLST)," September 22, 2011.
- Invited Speaker, National Cancer Advisory Board, "ACRIN: Studies to Evaluate the Impact of NLST Screening on Smoking Behaviors and Participant Quality of Life," June 28, 2011.
- Invited Speaker, Eastern Cooperative Oncology Group Annual Meeting, "Outcomes Data Collection in American College of Radiology Imaging Group Studies." June 10, 2011.
- Invited Panel member, FDA Public Workshop "Study Methodology for Diagnostics in the Post-Market Setting, May 12, 2011.
- Invited Panel Member, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging, April 22-23, 2010.
- Invited participant, National Cancer Institute, Non-Invasive Autopsy Workshop, March, 2003.
- Invited participant, National Cancer Institute/American Cancer Society, Lung Cancer Early Detection Workshop, March 7-8 2001, Washington, DC.
- Invited Speaker, Cochrane Collaboration. Invited speaker, Society for Health Services Research in Radiology Annual Meeting, October 1, 1999. Invited Speaker,
- Introduction to Epidemiologic Methods. Invited speaker, Society for Health Services Research in Radiology Annual Meeting, October 23, 1998.

ABSTRACTS

1. Dicostanzo D, **Gareen I**, Lesser M and Rosen, PP. Infiltrating lobular carcinoma (IFLC): a long term follow-up study of 176 patients. Presented at the International Academy of Pathology Annual Meeting, February 26, 1988.
2. **Gareen I**, Morgenstern H, and Greenland S. Explaining the association between maternal age and risk of cesarean delivery. Presented at the Society for Epidemiological Research Annual Meeting, June 13, 1997.
3. **Gareen I**, Greenland S, and Morgenstern H. Mixed and missing data categories in meta-analyses. Presented at the Society for Epidemiological Research Annual Meeting, June 26, 1998.
4. **Gareen I**, Morgenstern H, and Greenland S. Adverse outcomes of repeat elective cesarean section. Presented at the Society for Epidemiological Research Annual Meeting, June 26, 1998.
5. **Gareen I**, Aberle D, Black WC, Goldin J, Fryback D, Gatsonis C. Study design considerations for a multi-center randomized clinical trial to evaluate helical low-dose computed-tomography for lung cancer screening, Presented at the Society for Epidemiological Research Annual Meeting, June 15, 2000.
6. Mainiero M, **Gareen I**, Sheps B, Bird C, Cobb C, Smith W. Comparison of stereotactically-guided and ultrasound-guided core-needle biopsy with respect to procedure time and patient satisfaction. Presented at the Society for Epidemiological Research Annual Meeting, June 16, 2000.
7. Mainiero MB, Schepps B, **Gareen I**, Bird CE. Comparison of stereotactic and ultrasound-guided breast biopsy with respect to procedure time and patient satisfaction, Presented at the RSNA Annual Meeting, November 2000.
8. Dupuy DE, **Gareen IF**, Mayo-Smith WW, Vaccaro JP, Cronan JJ. The clinical utility of tissue harmonics

- imaging and abdominal ultrasound, Presented at the RSNA Annual Meeting, November 2000.
9. Mayo-Smith WW, Cobb CM, Smith W, **Gareen IF**, Dorfman GS. Comparison of hospital personnel costs using transportable versus fixed-platform CT scanners, Presented at the RSNA Annual Meeting, November 2000.
 10. Design and analysis considerations in the assessment of new diagnostic imaging technologies. **Gareen I**, Toledano A, Blume J, Gatsonis C. Presented at the Society for Epidemiological Research Annual Meeting, June 14, 2001.
 11. Aragaki C, Fischbach LA, Field C, Culica D, Mercer Q, Hynan L, Gatchel R, **Gareen I**, Coyle YM. A new method for analyzing quality of life: application to severe persistent asthma. Presented at the Causal Inference Conference, August 9-11, 2001.
 12. Delzell P, **Gareen I**, Petchprapa C, et al. Ultrasound of the Shoulder. Presented at RSNA, November 2001.
 13. Aragaki C, Fischbach L, Field C, Culica D, Mercer Q, Hynan L, Gatchel R, **Gareen I**, Coyle Y. An internet-based tool for patient-based decision analysis: application to severe persistent asthma. Presented at the Society for Epidemiologic Research Annual Meeting, June 2002
 14. **Gareen I**. Do we have enough information to conclude that there is no association between intrauterine device use and pelvic inflammatory disease? Presented at the Society for Epidemiologic Research Annual Meeting, June 2003.
 15. **Gareen I**. Issues to be considered when incorporating quality of life, health status, and other outcome measures into epidemiological research. Presented at the Society for Epidemiologic Research Annual Meeting, June 2003.
 16. **Gareen IF**, Clark M, Park E, Sicks J. Baseline smoking characteristics and intention to quit in participants enrolled in the American College of Radiology National Lung Screening Trial . Presented at the Society for Epidemiologic Research Annual Meeting, June 2004.
 17. **Gareen IF**, Clark M, Sicks J, Fryback D. The Impact Of Smoking Status And Smoking Cessation On Health Related Quality Of Life in the American College of Radiology Imaging Network National Lung Screening Trial Presented at the Society for Epidemiologic Research Annual Meeting, June 2004.
 18. **Gareen IF**, Potential confounding of the association between screening arm and cancer mortality in population-based screening trials by screening test-related factors. Presented at the Society for Epidemiologic Research Annual Meeting, June 2005.
 19. **Gareen IF**, Potential Factors that may Influence Measurement of Outcomes in Clinical Trials to Evaluate Screening Modalities. Presented at the Society for Epidemiologic Research Annual Meeting, June 2005.
 20. **Gareen IF**, The potential impact of differential non-compliance in screening trials. Presented at the Society for Epidemiologic Research Annual Meeting, June 2006.
 21. Park ER, **Gareen I**, Rakowski W, Ostroff J, Perry K, Rigotti NA. Risk Perceptions among participants of the National Lung Cancer Screening Trial. Presented at the Society of Behavioral Medicine's 28th Annual Meeting and Scientific Sessions, March 21-24, 2007.
 22. **Gareen IF**, Centralized data collection of participant-reported outcomes in multi-site American College of Radiology Imaging Network studies. Presented at the Society for Epidemiologic Research Annual Meeting, June 2007.
 23. **Gareen IF**, Collecting medical record information in a multi-center study. Presented at the Society for Epidemiologic Research Annual Meeting, June 2007.
 24. Siewert B, **Gareen I**, Vanness D, Herman B, Johnson CD, Gatsonis C. ACRIN 6664 - Patient acceptance and preference of CT colonography compared to optical colonoscopy for colon cancer screening. Presented

at ASCO, May 2009.

25. **Gareen IF**, Hillner BE, Siegel BA, Shields AF, Duan F, Hanna L, Stine SH, RE Coleman
The National Oncologic PET Registry: a Data Source for Health Services Research. Presented at the Society for Epidemiologic Research. June 2009.
26. Streck JS, **Gareen I**, Nichter M, Ostroff J, Rigotti NA, Hyland K, Park ER. Exploring risk perceptions following lung screening: a qualitative study among ACRIN National Lung Screening Trial (NLST) Participants. Presented at the SRNT Annual Meeting, March 2013.
27. **Gareen IF**, Duan F, Snyder BS, Sick J. Patient Reported outcome form response rates for two American College of Radiology Imaging Network Centralized cancer screening trials using a centralized administration model. Presented at the Society for Epidemiologic Research Annual Meeting 2013.
28. **Gareen IF**, Park E, et al. The effects of physician-delivered brief smoking cessation on ACRIN/NLST participants' smoking behaviors. Presented at ACSO 2013 Annual Meeting.
29. Lathan C, Park E, **Gareen I**, Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST). Presented at ASCO 2013 Annual Meeting.
30. Park E, **Gareen, I**, Sicks, J, Hyland K, Streck J, Ostroff J, Nichter M, Rigotti N. Lung screening's effect on perceived risk: implications for tobacco treatment. Presented at the Society of Behavioral Medicine, Philadelphia, Pennsylvania, April 2014.
31. Perez GK, **Gareen IF**, Kumar P, Lathan C, Sicks J, Hyland K, Park ER. Racial Differences in Smoking Behaviors Among Participants in The ACRIN National Lung Screening Trial (NLST). Presented at the Society for Research on Nicotine and Tobacco Annual Meeting February 2015.
32. Carlos RC, Snyder BS, Lehman CD, Khan SA, Sparano JA, Romanoff J, Gatsonis C, **Gareen IF**, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, r Comstock C, Wagner LI. Decision quality and quality of life after treatment for DCIS: A trial of the ECOG-ACRIN Cancer Research Group (E4112). Presented at the RSNA Annual Meeting, November, 2017.
33. Rabinovici GD, Gatsonis C, Apgar C, **Gareen IF**, Hanna L, Hendrix J, Hillner BE, Olson C, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC, and the IDEAS Study investigators, Impact Of Amyloid Pet On Patient Management: Early Results From The Ideas Study. Presented at the AAIC Meeting, London, July 2017.
34. Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, **Gareen I**, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, On behalf of the TAILORx Study Team. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS6-03.
35. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, **Gareen IF**, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev O, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC. Amyloid PET Leads to Frequent Changes in Management of Cognitively Impaired Patients: the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Plen01.001) Neurology Apr 2019, 92 (15 Supplement) Plen01.001;
36. Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SA, Gareen IF, Whelan TP, Sledge GW, Cella D, Wagner LI. Early Discontinuation to Adjuvant Endocrine Therapy in the TAILORx Trial. Presented at ASCO 2020.
37. Bradbury AR, Lee J-W, Gaieski JB, Li S, **Gareen IF**, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Gopakumar S, Hambudiri GS, Carlos RC, Wagner LI. Randomized trial of web-based genetic education

- versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program ,NCORP; (EAQ152) COMET trial. Presented at ASCO 2020).
38. Zhao F, Peipert JD, Lee JW, Hong F, Ip E, **Gareen I**, O'Connell NS, Carlos R, Mayer I, Miller K, Partridge A, Shanafelt T, Stewart K, Tarhini A, Thomas M, Weiss M, Sparano J, Cella D, Gray R, Wagner LI. Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. Presented at ASCO 2020.
 39. Peipert JD, Zhao F, Lee JW, Hong F, Ip E, **Gareen I**, O'Connell NS, Carlos R, Stewart K, Weiss M, Sparano J, Cella D, Gray R, Wagner LI. Increase in Side Effect Bother was Associated with Early Treatment Discontinuation in a Clinical Trial among Multiple Myeloma Patients. Presented at ASCO 2020.
 40. Pisano E, Gatsonis C, Schnall M, Yaffe M, Troester M, **Gareen I**, Collins L, Curtis A, Cole E, Carlos R, Miller K, Comstock C. ECOG-ACRIN Tomosynthesis Mammographic Imaging Screening Trial (EA1151). Presented at ASCO 2020.
 41. Pisano E, Gatsonis C, Schnall MD, Yaffe M, Troester MA, **Gareen IF**, Collins LC, Curtis A, Cole E, Cormack J, Carlos R, Miller K, Comstock C. Engaging the radiology community in the National Clinical Trials Network: The ECOG-ACRIN TMIST experience. Presented at ASCO 2021.
 42. Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Cella D, Zhao FM, Ip E, O'Connell N, Hong FX, Peipert J, **Gareen, IF**, Gray RJ, Wagner LI, Carlos R. Association between allostatic load symptom burden and mortality in E1A11 trial for myeloma. Presented at ASCO 2021.
 43. Kircher SM, Duan FH, **Gareen, IF**, Underwood E, Sicks J, Suga JMM, Kehn H, Mehan PT, Acoba JD, Taylor MA, Wagner LI, Carlos R. Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: Early results of ECOG-ACRIN EAQ162CD. Presented at ASCO 2021.
 44. Fazeli S, Snyder B, **Gareen, IF**, Lehman CD, Khan SA, Romanoff J, Gatsonis C, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller K, Sparano JA, Comstock C, Wagner LI, Carlos R. Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112). Presented at ASCO 2021.
 45. Peipert J, Zhao FM, Lee JW, Hong F, Shen SE, Ip E, O'Connell N, Graham N, Smith ML, **Gareen, I**, Carlos R, Obeng-Gyasi S, Kumar SK, Miller K, Partridge A, Shanafelt T, Sparano JA, Stewart K, Tarhini A, Thomas M, Weiss M, Cella D, Gray R, Wagner LI. Change in a single-item indicator of treatment tolerability in cancer is associated with early treatment discontinuation. Presented at Quality of Life Research 2021.
 46. O'Connell N, Zhao FM, Lee JW, Hong FG, Shen SE, Ip E, Salem W, Peipert J, Graham N, Smith ML, **Gareen, I**, Carlos R, Obeng-Gyasi S, Miller K, Partridge A, Shanafelt T, Sparano J, Stewart K, Tarhini A, Thomas M, Weiss M, Cella D, Wagner L, Gray R. Low and moderate grade adverse events are important contributors to patient-reported treatment side-effect bother. Presented at Quality of Life Research 2021.
 47. Zhao F, Peipert JD, Stearns V., Chang VT, Jegede O, Ip EH, Lee JW, O'Connell NS, Graham N, Henry NL, Loprinzi CL, Flynn PJ., Fisch MJ, **Gareen I**, Carlos RC, Smith ML, Cella D, Sparano JA, Gray RJ, Wagner LI. Presented at ASCO 2022.
 48. Pisano E, Gatsonis C, Schnall M, Yaffe M, Troester M, **Gareen I**, Collins L, Curtis A, Cole E, Cormack J, Steingrimsson J, Carlos R, Miller K, Comstock C. Adjusting the TMIST Study Design to Accommodate Slower than Expected Accrual: ECOG-ACRIN EA1151. Presented at ASCO 2022.
 49. Kircher SM, Duan F, Underwood E, **Gareen IF**, Sicks J, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DA, Dalia S, Acoba DJ, Taylor MA, Wagner L, Carlos RC. Longitudinal changes in financial

burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD. Presented at ASCO 2022.

50. Walter AW, Lee JW, **Gareen IF**, Kircher SM, Herman BA, Streck JM, Kumar SK, Mayer I, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, EA6141 Kyriakopoulos C, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land S, Ostroff JS, Park ER. Neighborhood socioeconomic gradients, tobacco use and cessation indicators among adults with cancer in the U.S. Presented at ASCO 2022.
51. Narayan V, Liu T, Song Y, Mitchell J, Sicks J, Gareen IF, Sun L, Denduluri S, Fisher CP, Manikowski J, Wojtowicz, M. Hypertension, cardiovascular events and survival in renal cell carcinoma and thyroid cancer patients treated with vegfr tyrosine kinase inhibitors. Presented at JACC March 6, 2023).
52. Kuhl CK, Gatsonis CG, Newstead G, Snyder BS, An N, **Gareen IF**, Bergin JT, Rahbar H, Sung JS, Jacobs J, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller K, Schnall MD, Comstock CE. Incidence Round Screening Performance among Women with Dense Breasts Undergoing Abbreviated Breast MRI and Digital Breast Tomosynthesis (ECOG-ACRIN EA1141) Presented at ASCO, June 2023.
53. Park ER, Ostroff JS, Sicks JD, Goshe BM, **Gareen IF**, Herman BA, Taurone A, Walter AW, Regan S, Rasmussen AW, Levy DE, Muzikansky A, Thompson MA, Lui M, Malloy L, Gonzalez I, Finkelstein-Fox L, Carlos RC, Wagner LI. Smoking Cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD). Presented at ASCO, June 2023.
54. Zebrack B, Cole S, Salsman JM, Wagner L, Duan F, **Gareen I**, Parsons SK, Evens A, Cheung C, Lux L, Ghazal LV, Kahl B, Prasad P, Dinner S. Social genomics as a framework for understanding health disparities among adolescent and young adult cancer survivors. Presented at the NASEM workshop on Biological Effectors of social determinants of health in cancer February 20-21 2024.
55. Rosen RL, Sicks J, Park E, Ostroff J, Streck J, Goshe B, **Gareen IF**, Herman B, Taurone A, Walter AW, Regan S, Rasmussen A, Levy D, Muzikansky A, Thompson MA, Lui M, Malloy L, Gonzalez I, Finkelstein-Fox L, Munson ND, Greenwade MM, King DM, Jenigiri B, Burnette BL, Throckmorton AD, Ghamande SA, Siva D, Carlos RC, Wagner LI. Alcohol and tobacco co-use among cancer patients receiving virtual tobacco treatment: ECOG-ACRIN EAQ171CD. Presented at SRNT 2024.

GRANTS

Grants in Progress

1. Ilana F. Gareen PI, FOLD Study: Follow-up for Long-term Downstream cardiac outcomes associated with cancer treatment: Study participants will complete brief electronic questionnaires on a regular basis in response to text message phone prompts. The goal will be early detection of potential cardiotoxic side effects of chemotherapy. This study will generate better data on cardiotoxicity prevalence. The tool offers an opportunity for early detection of cardiotoxic side effects. Anticipated submission February 2025.
2. Ilana F. Gareen PI, Significant Incidental Findings detected at community lung screening: The goal of this project is to understand the morbidity, mortality, and healthcare utilization associated with detection of significant incidental findings (SIFs) on low-dose CT at community lung cancer screening, and to determine if the findings from the National Lung Screening Trial generalize to community practice. Anticipated Submission February 2025.

Current Grants

1. Ilana F. Gareen, PI, National Cancer Institute, Lung Screening: Efficacy versus Effectiveness: The goal of this project is to compare the efficacy of lung screening in community practice with that reported in the National Lung Screening Trial (NLST) with respect to the rate and type of abnormalities suspicious for

- lung cancer, the rate and type of significant incidental findings that are seen on lung screening and may be clinically important, but that are not related to lung cancer, and the diagnostic testing that is done to evaluate lung and other abnormalities. (R01 CA215240), 01/17/2018 – 12/31/2024 (NCE), \$3,038,662
2. Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Network Group Statistics and Data Management Center: This subcontract covers support for the operations of Brown office of the Statistics and Data Management Center (SDMC) of ECOG-ACRIN Cancer Research Group. (Statistical Core subaward #1800006) (U10 CA180794), 04/29/2014 – 02/28/2025, \$9,254,000
 3. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Tomosynthesis Mammographic Imaging Screen Trial: (TMIST): The project lead and team will assist with the oversight and implementation of TMIST, (UG1 CA189828-06-BRWN3), 08/01/2017 – 07/31/2025, \$10,290,710
 4. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base: This project involves organizing and operating a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies in Cancer Care Delivery Research (CCDR). – CCDR (UG1 CA189828-06-BRWN2), 08/01/2014 – 07/31/2025, \$1,410,414
 5. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base: This project involves organizing and operating a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies covering cancer prevention, control, and screening. – CT (UG1 CA189828-06-BRWN1), 08/01/2014 – 07/31/2025, \$1,414,745
 6. Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, ACR, Imaging Dementia - Evidence for Amyloid Scanning Study: A Study to Improve Precision in Amyloid PET Coverage and Patient Care: The Center for Statistical Sciences (CSS), Brown University will be responsible for overseeing all data collection, review and analysis efforts associated with the New IDEAS Study, 07/01/2020 – 12/31/2027, \$892,982
 7. Bradley Zebrack, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Cancer Survivors: The proposed study intends to identify and define functional genomic pathways through which psychosocial and social environmental risk and resilience factors influence gene regulation in AYAs, and thus contribute to a greater understanding of health disparities in post-treatment survivorship (1R01 CA261752), 09/01/2021 – 08/31/2026, \$1,110,813
 8. Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving medication adherence using a CONNected CUsTOMized Treatment Platform (CONCURxP): This project intends to test an mHealth intervention to improve Palbociclib adherence by conducting a randomized controlled trial (RCT) of a CONNected CUsTOMized Treatment Platform (CONCURxP) vs. enhanced usual care. (1R01 CA262312-01A1), 08/01/22 – 07/31/27, \$955,099
 9. Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer patients: Our goals are to (1) assess intervention effectiveness, by comparing proportions of patients in the enhanced usual care and CostCOM intervention who develop behavioral, psychosocial and material financial hardship and experience “sticker shock” and/or surprise billing at 12 months; (2) To assess the short-term psychological effect of OOP cost communication independent from the combined effect with financial navigation; (3) To assess the moderator effect of financial self-efficacy on intervention effectiveness between two groups; (4) To explore the processes of implementation and dissemination (accuracy of OOP cost estimates, satisfaction with care, acceptability, adoption, appropriateness, fidelity, penetration/reach, and sustainability) of our intervention at community oncology sites. (R01 CA272680), 12/01/22 – 11/30/27, \$908,658
 10. Lynne Wagner, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Randomized controlled trial of

FoRtitude: Targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors in community oncology settings; This study addresses the recently identified need for accessible CBT-based interventions by both developing and deploying a user-centered eHealth intervention, as well as establishing feasibility through a multi-site collaboration with three NCI Community Oncology Research Program (NCORP) Sites. This study implements randomized controlled trial (RCT), 07/01/2024-06/30/29, \$697,936.

11. Dominique Michaud, PI, Ilana F. Gareen, Co-I, National Institutes of Health, Using DNA methylation array data to improve risk stratification and identification of lung cancers in the National Lung Screening Trial. (R01 CA280815), 08/20/23—3/31/2027, \$408,278.
12. John Salsman PI, Ilana F. Gareen, Co-I, Addressing financial hardship in adolescent and young adult cancer survivors: Efficacy and implementation of a multilevel intervention in community-based oncology practices: The goal of this project is to conduct a mixed-methods study in order to elucidate multi-level predictors of financial hardship and provide a robust evidence-base for future financial interventions among young adult cancer survivors, (R01CA282653-01A1),07/01/2024-06/30/29, \$900,585.
13. Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, ACR, The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), The Center for Statistical Sciences (CSS), Brown University will be responsible for monitoring and reporting progress in Alz-Net participant accrual and data collection, reviewing data completeness and quality, planning and implementing data analyses, collaborating in the development of reports and manuscripts, and addressing methodologic issue arising in Alz-Net. The Alz-Net statistical team has experience in clinical trials and observational studies of chronic disease, including Alzheimer’s Dementia, and also expertise in linking registry data with data from health care providers and health insurance in the public and private sectors, 01/01/2023 – 12/31/2029, \$2,062,048.
14. Joseph Sparano PI, Ilana F. Gareen Co-I, Breast Cancer Research Program (BCRP), Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), Dept. of the Army – USAMRAA, TAILORx-RxPONDER Clinical Research Extension Award: Advancing Progress, Precision, and Equity in Breast Cancer Care: Upon completion of this project, it is expected that the 21-gene RS and SET Index will be used in combination to guide use of adjuvant chemotherapy use with greater precision than currently possible with the RS alone, sparing additional patients unneeded chemotherapy, and identifying some who would derive a large chemotherapy benefit but otherwise would not have been advised to receive chemotherapy based on the RS results alone, (BC221354), 09/2023 – 08/2027, \$39,657.

Completed Grants

1. Ilana F Gareen, PI, National Cancer Institute, Outcomes Associated with Significant Incidental Findings in Lung Cancer Screening (R01 CA204222), 03/17/2017 – 02/28/2023 (NCE), \$1,254,419
2. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (Patient-Reported Outcomes Component: PRO) (UG1 CA189828-06-BRWN-EA2185-PCyst), 10/01/2019 –07/31/2023, \$1,500,000
3. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (Cost-Effectiveness Analysis Component: CEA) (UG1 CA189828-06-BRWN-EA2185-CEA), 10/01/2019 –07/31/2023, \$1,500,000
4. Elyse Park, PI, Ilana F. Gareen, Co-PI, National Cancer Institute, Implementing a Virtual Tobacco Treatment in Community Oncology Practices (R01 CA214427), 02/01/2018 – 07/31/2023, \$247,172
5. John Salsman, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN NCORP Trial (UG1CA189828), 08/01/2020 – 07/31/2022, \$347,246
6. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Developing an Analytic Resource for

- Efficiently Linking EA Participants to Medicare data to identify patients with Alzheimer's disease and its related dementias (DAREtoLEAP) (3UG1 CA189828-08S1), 08/01/2021 – 07/31/2022, \$296,089
7. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – COVID19 Supplement (5UG1CA189828-07S3), 08/01/2020 – 07/31/2022, \$88,727
 8. Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability in ECOG-ACRIN Studies (U01 CA233169), 09/01/2018 – 08/31/2023, \$191,656
 9. Bonnie Ky, PI, Ilana F. Green, Co-I, National Heart, Lung, and Blood Institute, Planning Grant for CARISMA – Cancer Therapy Risk-reduction with Intensive Systolic BP Management (R34 HL146927), 08/01/2019 – 07/31/2022, \$283,385
 10. Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, American College of Radiology, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study, 06/01/15 – 12/31/20, \$3,217,134
 11. Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning, 09/15/17 – 05/31/21, \$690,943
 12. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (PCyst), 10/01/2019 – 07/31/2027, \$3,299,994
 13. Apgar, Ilana F. Gareen, Co-I, ACR Foundation, EA1141 Abbreviated MRI Study, 09/16/21 – 08/31/21, \$53,021
 14. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – EASEE PRO, 08/01/18 – 07/31/19, \$19,947
 15. Ilana F. Gareen, PI, NCI-NHGRI, NCI-NHGRI Precision Medicine Ancillary Studies – COMET, 03/01/17 – 02/28/18, \$79,413
 16. Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning CARE IDEAS, 08/01/16 – 7/31/17, \$1,373,989
 17. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – Incorporating the C-TUQ among NCTN and NCORP Clinical Trial Participants, 08/01/16 – 07/31/17, \$80,694
 18. Fenghai Duan, PI, Ilana F. Gareen, Co-I, Blue Earth Diagnostics, Blue Earth Diagnostics Multi-Center Trial of FACBC, 08/01/16 – 07/31/19, \$61,097
 19. Fenghai Duan/Ilana F. Gareen (MPIs), World Molecular Imaging Society, NOPR NaF CMS Collaboration, 01/01/17 – 12/31/17, \$136,698
 20. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, Agency for Healthcare Research and Quality, ACRIN NLST Follow-Up, 03/01/16 – 02/28/17, \$15,000
 21. Ilana F. Gareen PI, American College of Radiology, ACRIN Protocol 7151 Statistical Support, 04/01/11 – 12/31/15, total awarded \$268,000.
 22. Constantine Gatsonis/ Mitchell Schnall MPI, Ilana F. Gareen Co-I, National Cancer Institute, NCI/ECOG-ACRIN NCORP Research Base-CT (1UG1CA189828-01-BRWN1) 08/01/14 – 07/31/16, total awarded \$410,072.
 23. Constantine Gatsonis/ Mitchell Schnall (MPIs) , Ilana F. Gareen Co-I, NCI/ECOG-ACRIN NCORP Research Base - CCDR, National Cancer Institute (1UG1CA189828-01-BRWN2), 08/01/14 – 07/31/16, total awarded \$312,044.
 24. Constantine Gatsonis PI, Ilana F. Gareen Co-I, ACR Foundation, RESCUE: Randomized Evaluation of

- Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/13-09/29/15, total awarded \$317,926.
25. Constantine Gatsonis/ Ilana F. Gareen (MPIs), National Cancer Institute, Biostatistics Data Management Center for ACRIN National Lung Screening Trial Supplement (U10 CA79778), 07/01/02 - 12/31/14, total awarded \$23,442,291.
 26. Constantine Gatsonis PI, Ilana F. Gareen Co-I National Cancer Institute, Biostatistics Data Management Center for ACRIN (U10 CA79778), 03/01/99-12/31/14, total awarded \$17,951,912.
 27. Constantine Gatsonis PI, Ilana F. Gareen Co-I, Agency for Healthcare Research, RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/10-09/29/13, total awarded \$2,071,559.
 28. Anna Tosteson PI, Constantine Gatsonis/Ilana F. Gareen Co-Sub PI, National Cancer Institute, Grand Opportunity Grant: Comparative Effectiveness of Advanced Imaging in Cancer, National Cancer Institute, RC2 CA148259, Subcontract to Dartmouth University, 09/30/09-05/31/13, total awarded \$2,071,559.
 29. Constantine Gatsonis PI, Ilana F. Gareen Co-I Investigator, Academy of Molecular Imaging, National Oncologic PET Registry (NOPR), [PI: Gatsonis], 05/01/06-12/31/13, total awarded \$1,207,017.
 30. Constantine Gatsonis PI , Ilana F. Gareen Co-I, Patient Centered Outcomes Research Institute, Standards in the Design, Conduct, and Evaluation of Research Evaluating Diagnostic Testing Strategies for Patient Centered Outcomes, 01/04/12-06/15/12, total awarded \$77,868.
 31. Ilana F. Gareen PI, National Cancer Institute, Compliance with Lung Cancer Screening, National Cancer Institute (R03 CA 139584), 06/01/09-05/31/12, total awarded \$149,895.
 32. Constantine Gatsonis, Ilana F. Gareen Co-I, National Cancer Institute, Biostatistics Data Management Center for Computerized Tomographic Colonography Trial (CTC) (5U01 CA 079778-09), 01/01/05-12/31/09, total awarded \$1,244,061.
 33. Constantine Gatsonis, Ilana F. Gareen Co-I National Cancer Institute/American College of Radiology Subcontract Co-Investigator, ACRIN Fellowship (CA94032), 01/01/03-08/31/05, total awarded \$160,552.

UNIVERSITY TEACHING

Instructor

2005, 2009-2020, 2024	Clinical Trials Methodology
2002-2007	Community Health Fellows Didactic Sessions
2001-2004	Health and Human Reproduction
2000	Advanced Epidemiologic Methods

MENTORING

Post-Doctoral

2022-present	Research Mentor	Brett Diamond MD
2021-2023	Research Mentor	Men-Yun Lin, Post-Doctoral Fellow, Wake Forest University
2005-2010	Mentored Research Scholar Grant - American Cancer Society, The Effect of Lung Cancer Screening on Risk Perceptions	Elyse Park

2001- 2004 Research Mentor ACRIN Fellows

Doctoral

2018-2023 Doctoral Committee Member Jerson Cochancela

2018-2022 Doctoral Committee Chair Nana Boame

2017-2018 Research Mentor Stephannie Shih

2015-2017 Doctoral Committee Member Valerie Strezsak

2002-2004 Doctoral Committee Member Mei-Hsui Chen

Masters

2023-present MPH Thesis Advisor KunYang MD

2022-present MPH Thesis Advisor Kevin Xi

2022-2023 MPH Thesis Advisor Yuchen Bo

2020 MPH Thesis Advisor Nishtha Baranwal

Undergraduate

2002 Independent Study Justine Woodfield